These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
242 related items for PubMed ID: 28899740
1. Histone 3.3 mutations in giant cell tumor and giant cell-rich sarcomas of bone. Righi A, Mancini I, Gambarotti M, Picci P, Gamberi G, Marraccini C, Dei Tos AP, Simi L, Pinzani P, Franchi A. Hum Pathol; 2017 Oct; 68():128-135. PubMed ID: 28899740 [Abstract] [Full Text] [Related]
2. Mutation Analysis of H3F3A and H3F3B as a Diagnostic Tool for Giant Cell Tumor of Bone and Chondroblastoma. Cleven AH, Höcker S, Briaire-de Bruijn I, Szuhai K, Cleton-Jansen AM, Bovée JV. Am J Surg Pathol; 2015 Nov; 39(11):1576-83. PubMed ID: 26457357 [Abstract] [Full Text] [Related]
3. H3F3A G34 mutation DNA sequencing and G34W immunohistochemistry analysis in 366 cases of giant cell tumors of bone and other bone tumors. Gong L, Bui MM, Zhang W, Sun X, Zhang M, Yi D. Histol Histopathol; 2021 Jan; 36(1):61-68. PubMed ID: 33021329 [Abstract] [Full Text] [Related]
4. Diagnostic value of histone 3 mutations in osteoclast-rich bone tumors. Nohr E, Lee LH, Cates JM, Perizzolo M, Itani D. Hum Pathol; 2017 Oct; 68():119-127. PubMed ID: 28882701 [Abstract] [Full Text] [Related]
5. Detection of H3F3A p.G35W and p.G35R in giant cell tumor of bone by Allele Specific Locked Nucleic Acid quantitative PCR (ASLNAqPCR). Gamberi G, Morandi L, Benini S, Resca A, Cocchi S, Magagnoli G, Donati DM, Righi A, Gambarotti M. Pathol Res Pract; 2018 Jan; 214(1):89-94. PubMed ID: 29254795 [Abstract] [Full Text] [Related]
6. H3F3 mutation status of giant cell tumors of the bone, chondroblastomas and their mimics: a combined high resolution melting and pyrosequencing approach. Kervarrec T, Collin C, Larousserie F, Bouvier C, Aubert S, Gomez-Brouchet A, Marie B, Miquelestorena-Standley E, Le Nail LR, Avril P, Christophe Pagès J, de Pinieux G. Mod Pathol; 2017 Mar; 30(3):393-406. PubMed ID: 28059095 [Abstract] [Full Text] [Related]
7. Diagnostic utility of histone H3.3 G34W, G34R, and G34V mutant-specific antibodies for giant cell tumors of bone. Yamamoto H, Iwasaki T, Yamada Y, Matsumoto Y, Otsuka H, Yoshimoto M, Kohashi K, Taguchi K, Yokoyama R, Nakashima Y, Oda Y. Hum Pathol; 2018 Mar; 73():41-50. PubMed ID: 29241742 [Abstract] [Full Text] [Related]
14. H3F3A mutation as a marker of malignant giant cell tumor of the bone: A case report and review of literature. Ratnagiri R, Uppin S. J Cancer Res Ther; 2023 Mar; 19(3):832-834. PubMed ID: 37470622 [Abstract] [Full Text] [Related]
17. H3F3A (Histone 3.3) G34W Immunohistochemistry: A Reliable Marker Defining Benign and Malignant Giant Cell Tumor of Bone. Amary F, Berisha F, Ye H, Gupta M, Gutteridge A, Baumhoer D, Gibbons R, Tirabosco R, O'Donnell P, Flanagan AM. Am J Surg Pathol; 2017 Aug; 41(8):1059-1068. PubMed ID: 28505000 [Abstract] [Full Text] [Related]
18. Histone H3.3 mutation in giant cell tumor of bone: an update in pathology. Yamamoto H, Ishihara S, Toda Y, Oda Y. Med Mol Morphol; 2020 Mar; 53(1):1-6. PubMed ID: 31748824 [Abstract] [Full Text] [Related]